In tumors, CTLA-4 and PD-1/PD-L1 can favor tumor evasion from immune surveillance, so that their inhibition can produce an increased immune activation and overcome the typical tumor-induced immunosuppression [18,19]. Here, CTLA4 is linked to neoplasm.